These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1154 related articles for article (PubMed ID: 34348067)

  • 1. Anti-inflammatory effects of GLP-1 in patients with COVID-19.
    Sazgarnejad S; Yazdanpanah N; Rezaei N
    Expert Rev Anti Infect Ther; 2022 Mar; 20(3):373-381. PubMed ID: 34348067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
    Belančić A; Kresović A; Troskot Dijan M
    Clin Obes; 2021 Apr; 11(2):e12439. PubMed ID: 33423388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
    Banerjee Y; Pantea Stoian A; Silva-Nunes J; Sonmez A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1309-1315. PubMed ID: 34424130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
    Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.
    Hariyanto TI; Intan D; Hananto JE; Putri C; Kurniawan A
    Diabetes Res Clin Pract; 2021 Sep; 179():109031. PubMed ID: 34461139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.
    Song ZH; Huang QM; Xu SS; Zhou JB; Zhang C
    Ther Innov Regul Sci; 2024 Jul; 58(4):773-787. PubMed ID: 38683419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension.
    Lee JH
    Med Hypotheses; 2022 Jan; 158():110739. PubMed ID: 34916733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
    Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
    Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1R agonists for the treatment of obesity: a patent review (2015-present).
    Liu C; Zou Y; Qian H
    Expert Opin Ther Pat; 2020 Oct; 30(10):781-794. PubMed ID: 32799587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated patent review of GLP-1 receptor agonists (2020-present).
    Lu W; Zhou Z; Jiang N; Han J
    Expert Opin Ther Pat; 2023; 33(9):597-612. PubMed ID: 37870067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.